Lupus Nephritis Clinical Trials

45 recruiting

Lupus Nephritis Trials at a Glance

66 actively recruiting trials for lupus nephritis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 23 trials, with the heaviest enrollment activity in New York, Atlanta, and Nanjing. Lead sponsors running lupus nephritis studies include China Immunotech (Beijing) Biotechnology Co., Ltd., Novartis Pharmaceuticals, and Sohag University.

Browse lupus nephritis trials by phase

Treatments under study

About Lupus Nephritis Clinical Trials

Looking for clinical trials for Lupus Nephritis? There are currently 45 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lupus Nephritis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lupus Nephritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 66 trials

Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Phase 2

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

Lupus Nephritis
Autolus Limited35 enrolled26 locationsNCT07053800
Recruiting
Phase 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled93 locationsNCT07015983
Recruiting
Phase 2

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Lupus Nephritis
Novartis Pharmaceuticals240 enrolled103 locationsNCT05268289
Recruiting

Lupus Landmark Study: A Prospective Registry and Biorepository

Systemic Lupus Erythematosus (SLE)Lupus NephritisNeuropsychiatric Systemic Lupus Erythematosus
Lupus Research Alliance3,500 enrolled25 locationsNCT05934149
Recruiting
Phase 1Phase 2

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting
Phase 1

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Lupus Nephritis (LN)
Regeneron Pharmaceuticals90 enrolled11 locationsNCT06975787
Recruiting
Phase 1Phase 2

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus ErythematosusLupus Nephritis
Cabaletta Bio28 enrolled23 locationsNCT06121297
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Lupus Nephritis
Hoffmann-La Roche40 enrolled42 locationsNCT05039619
Recruiting

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Lupus Nephritis
GlaxoSmithKline300 enrolled5 locationsNCT06527872
Recruiting
Phase 1

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Lupus Nephritis (LN)Systemic Lupus Erthematosus (SLE)Extra-renal Lupus (ERL)
Hinge Bio30 enrolled1 locationNCT07491900
Recruiting
Phase 3

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 2

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Lupus Nephritis
Children's Hospital Medical Center, Cincinnati105 enrolled19 locationsNCT05538208
Recruiting
Phase 3

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Lupus Nephritis
Novartis Pharmaceuticals315 enrolled25 locationsNCT06711887
Recruiting
Phase 2

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Nanjing University School of Medicine50 enrolled1 locationNCT07340463
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital18 enrolled1 locationNCT06585514
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Lupus NephritisPrimary Membranous Nephropathy
Nkarta, Inc.96 enrolled16 locationsNCT06557265
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1Phase 2

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947473
Recruiting
Phase 1Phase 2

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947460